Predicting recurrence of nonfunctioning pituitary adenomas

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 11, 2009, Pages 4406-4413

  Noh, Tae Woong ^a   Hyeong, Jae Jeong ^b   Lee, Mi Kyung ^a   Tai, Seung Kim ^a   Sun, Ho Kim ^a   Eun, Jig Lee ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN; PROTEIN KINASE B; SECURIN; UNCLASSIFIED DRUG; ZAC1 PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NICK END LABELING; NONFUNCTIONING PITUITARY ADENOMA; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURGICAL TECHNIQUE; TISSUE MICROARRAY; TUMOR RECURRENCE;

EID: 70449135219     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-0471     Document Type: Article

References (34)

1. Shomali ME, Katznelson L 2002 Medical therapy of gonadotropin-producing and nonfunctioning pituitary adenomas. Pituitary 5:89-98
2. Donovan LE, Corenblum B 1995 The natural history of the pituitary incidentaloma. Arch Intern Med 155:181-183
3. Mortini P, Barzaghi R, Losa M, Boari N, Giovanelli M 2007 Surgical treatment of giant pituitary adenomas: strategies and results in a series of 95 consecutive patients. Neurosurgery 60:993-1002; discussion 1003-1004
4. Losa M, Mortini P, Barzaghi R, Ribotto P, Terreni MR, Marzoli SB, Pieralli S, Giovanelli M 2008 Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J Neurosurg 108:525-532 (Pubitemid 351357985)
5. Snead FE, Amdur RJ, Morris CG, Mendenhall WM 2008 Long-term outcomes of radiotherapy for pituitary adenomas. Int J Radiat Oncol Biol Phys 71:994-998
6. Kontogeorgos G 2006 Predictive markers of pituitary adenoma behavior. Neuroendocrinology 83:179-188 (Pubitemid 44578870)
7. Theodoropoulou M, Zhang J, Laupheimer S, Paez-Pereda M, Erneux C, Florio T, Pagotto U, Stalla GK 2006 Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res 66:1576-1582 (Pubitemid 43259940)
8. Persad S, Attwell S, Gray V, Delcommenne M, Troussard A, Sanghera J, Dedhar S 2000 Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA 97:3207-3212 (Pubitemid 30183280)
9. Bryson PC, Shores CG, Hart C, Thorne L, Patel MR, Richey L, Farag A, Zanation AM 2008 Immunohistochemical distinction of follicular thyroid adenomas and follicular carcinomas. Arch Otolaryngol Head Neck Surg 134:581-586 (Pubitemid 351871015)
10. Gejman R, Swearingen B, Hedley-Whyte ET 2008 Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum Pathol 39:758-766 (Pubitemid 351601606)
11. Kapranos N, Kontogeorgos G, Horvath E, Kovacs K 2004 Morphology, molecular regulation and significance of apoptosis in pituitary adenomas. Front Horm Res 32:217-234
12. Datta SR, Brunet A, Greenberg ME 1999 Cellular survival: a play in three Akts. Genes Dev 13:2905-2927
13. Musat M, Korbonits M, Kola B, Borboli N, Hanson MR, Nanzer AM, Grigson J, Jordan S, Morris DG, Gueorguiev M, Coculescu M, Basu S, Grossman AB 2005 Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocr Relat Cancer 12:423-433 (Pubitemid 40896456)
14. Vivanco I, Sawyers CL 2002 The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2:489-501 (Pubitemid 37328931)
15. Vlotides G, Cruz-Soto M, Rubinek T, Eigler T, Auernhammer CJ, Melmed S 2006 Mechanisms for growth factor-induced pituitary tumor transforming gene-1 expression in pituitary folliculostellate TtT/GF cells. Mol Endocrinol 20:3321-3335 (Pubitemid 44834329)
16. Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V, Ferrandina G, Benedetti Panici P, Mancuso S, Neri G, Testa JR 1995 Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64:280-285
17. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, Testa JR 1996 Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA 93:3636-3641 (Pubitemid 26127592)
18. Ringel MD, Hayre N, Saito J, Saunier B, Schuppert F, Burch H, Bernet V, Burman KD, Kohn LD, Saji M 2001 Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Research 61:6105-6111 (Pubitemid 32762546)
19. Nicholson KM, Anderson NG 2002 The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14:381-395
20. Staal SP 1987 Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 84:5034-5037
21. Bellacosa A, Testa JR, Staal SP, Tsichlis PN 1991 A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 254:274-277 (Pubitemid 21917339)
22. Thompson FH, Nelson MA, Trent JM, Guan XY, Liu Y, Yang JM, Emerson J, Adair L, Wymer J, Balfour C, Massey K, Weinstein R, Alberts DS, Taetle R 1996 Amplification of 19q13.1-q13.2 sequences in ovarian cancer. G-band, FISH, and molecular studies. Cancer Genet Cytogenet 87:55-62
23. Nakatani K, Thompson DA, Barthel A, Sakaue H, Liu W, Weigel RJ, Roth RA 1999 Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 274:21528-21532 (Pubitemid 129519688)
24. Ruggeri BA, Huang L, Wood M, Cheng JQ, Testa JR 1998 Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog 21:81-86 (Pubitemid 28122842)
25. Hou P, Ji M, Xing M 2008 Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer 113:2440-2447
26. Lu C, Willingham MC, Furuya F, Cheng SY 2008 Activation of phosphatidylinositol 3-kinase signaling promotes aberrant pituitary growth in a mouse model of thyroid-stimulating hormone-secreting pituitary tumors. Endocrinology 149:3339-3345 (Pubitemid 351919619)
27. An JJ, Cho SR, Jeong DW, Park KW, Ahn YS, Baik JH 2003 Antiproliferative effects and cell death mediated by two isoforms of dopamine D2 receptors in pituitary tumor cells. Mol Cell Endocrinol 206:49-62
28. Theodoropoulou M, Arzberger T, Gruebler Y, Jaffrain-Rea ML, Schlegel J, Schaaf L, Petrangeli E, Losa M, Stalla GK, Pagotto U 2004 Expression of epidermal growth factor receptor in neoplastic pituitary cells: evidence for a role in corticotropinoma cells. J Endocrinol 183:385-394 (Pubitemid 39562718)
29. Kontogeorgos G, Stefaneanu L, Kovacs K, Cheng Z 1996 Localization of epidermal growth factor (EGF) and epidermal growth factor receptor (EGFr) in human pituitary adenomas and nontumorous pituitaries: an immunocytochemical study. Endocr Pathol 7:63-70 (Pubitemid 126717328)
30. Yu R, Melmed S 2001 Oncogene activation in pituitary tumors. Brain Pathol 11:328-341
31. Childs GV, Rougeau D, Unabia G 1995 Corticotropin-releasing hormone and epidermal growth factor: mitogens for anterior pituitary corticotropes. Endocrinology 136:1595-1602
32. Bertherat J, Chanson P, Montminy M 1995 The cyclic adenosine 3′,5′-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas. Mol Endocrinol 9:777-783
33. Lee EJ, Duan WR, Kotlar T, Jameson JL 2001 Restoration of growth hormone-releasing hormone (GHRH) responsiveness in pituitary GH3 cells by adenovirus-directed expression of the human GHRH receptor. Endocrinology 142:414-420 (Pubitemid 32183703)
34. Pagotto U, Arzberger T, Theodoropoulou M, Grübler Y, Pantaloni C, Saeger W, Losa M, Journot L, Stalla GK, Spengler D 2000 The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas. Cancer Res 60:6794-6799 (Pubitemid 32059140)